{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:45:23Z","timestamp":1791834323267,"version":"4.3.4"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Scientific Research in Flanders (FWO)"},{"name":"\u2018Onderzoeksfonds\u2019 of the KU Leuven in Belgium"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ejpb.2015.01.001","type":"journal-article","created":{"date-parts":[[2015,1,12]],"date-time":"2015-01-12T02:16:33Z","timestamp":1421028993000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies"],"prefix":"10.1016","volume":"90","author":[{"given":"Jef","family":"Stappaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Geboers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.01.001_b0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1124\/dmd.106.013862","article-title":"Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum","volume":"35","author":"Masaki","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2015.01.001_b0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ejpb.2011.11.011","article-title":"Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids","volume":"80","author":"Borde","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejpb.2015.01.001_b0015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijpharm.2006.12.011","article-title":"In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation","volume":"336","author":"Brouwers","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.001_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2006.01.050","article-title":"Stability of valacyclovir: implications for its oral bioavailability","volume":"317","author":"Granero","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.001_b0025","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1128\/AAC.42.10.2602","article-title":"Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability","volume":"42","author":"Stoeckel","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2015.01.001_b0030","unstructured":"EMA (CHMP), Assessment Report for Zytiga (Abiraterone), 2011. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002321\/WC500112860.pdf>."},{"key":"10.1016\/j.ejpb.2015.01.001_b0035","unstructured":"FDA (CDER), Clinical Pharmacology and Biopharmaceutics Review(s) \u2013 Abiraterone Acetate, 2010. <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202379Orig1s000ClinPharmR.pdf> <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/202379Orig1s000ClinPharmR.pdf> (accessed 15.09.14)."},{"key":"10.1016\/j.ejpb.2015.01.001_b0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00498254.2012.721022","article-title":"A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects","volume":"43","author":"Acharya","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2015.01.001_b0045","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/mp100377m","article-title":"Excipient-mediated supersaturation stabilization in human intestinal fluids","volume":"8","author":"Bevernage","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.001_b0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0169-409X(00)00130-7","article-title":"Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract","volume":"46","author":"H\u00f6rter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.01.001_b0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/1389200033489253","article-title":"Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist","volume":"4","author":"Beaumont","year":"2003","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejpb.2015.01.001_b0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpb.2012.07.009","article-title":"Drug precipitation\u2013permeation interplay: supersaturation in an absorptive environment","volume":"82","author":"Bevernage","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T10:50:23Z","timestamp":1566211823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":12,"alternative-id":["S0939641115000028"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.01.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}